Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
Jia Jun Weng,*,1 Li Hua Wang,*,1 Hao Zhu,2 Wen Rong Xu,1 Yu Mei Wei,1 Zhi Yang Wang,1 Wen Juan Yu,1 Hua Fang Li1,3–41Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University of Medicine, Shanghai, People’s Republic of China; 2Department of Anesthesio...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ae1f261d9a0849728efebc5889ba9b88 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ae1f261d9a0849728efebc5889ba9b88 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ae1f261d9a0849728efebc5889ba9b882021-12-02T08:38:18ZEfficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study1178-2021https://doaj.org/article/ae1f261d9a0849728efebc5889ba9b882019-08-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-low-dose-d2d3-partial-agonist-pramipexole-on-neuroleptic-i-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Jia Jun Weng,*,1 Li Hua Wang,*,1 Hao Zhu,2 Wen Rong Xu,1 Yu Mei Wei,1 Zhi Yang Wang,1 Wen Juan Yu,1 Hua Fang Li1,3–41Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University of Medicine, Shanghai, People’s Republic of China; 2Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University of Medicine, Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Psychotic Disorders, Shanghai, People’s Republic of China; 4Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workObjective: Some lines of evidence show that D2/D3 receptor partial agonist pramipexole may be effective in the treatment of extrapyramidal symptoms (EPS) and psychiatric symptoms of schizophrenia. Therefore, we analyzed whether a low dose of pramipexole (0.375–0.75 mg/day) has efficacy on EPS and symptoms of schizophrenia while maintaining tolerability.Methods: Ten subjects with EPS [including drug-induced parkinsonism (DIP) and akathisia] were recruited in a stage-1, open-label pilot study. All the subjects were treated with a low dose of pramipexole. The evaluations were performed at baseline, day 3, week 1, week 2, week 4, week 6, and week 8. The ratings of SAS, BARS, PANSS, CDSS, and CGI-S and adverse effects (AE) were recorded in every visit.Results: SAS total scores decreased significantly during the study in patients with DIP (P<0.001), and mild AEs were detected. Treatments with pramipexole did not show an anti-akathisia effect during the study, while 2 subjects experienced deterioration of akathisia and mood symptoms. The psychiatric symptoms of schizophrenia showed a trend of improvement during the study, but there was no improvement in depressive mood.Conclusion: A low dose of pramipexole can significantly relieve antipsychotic-induced parkinsonism, but not akathisia. Improvements in psychiatric symptoms of schizophrenia were found, but the results of this study need to be validated in a larger sample. No improvement of mood disorder was detected.Keywords: extrapyramidal symptoms, antipsychotics, pramipexole, clinical trialWeng JJWang LHZhu HXu WRWei YMWang ZYYu WJLi HFDove Medical PressarticleExtrapyramidal symptomsAntipsychoticsPramipexoleClinical TrialNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2195-2203 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Extrapyramidal symptoms Antipsychotics Pramipexole Clinical Trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Extrapyramidal symptoms Antipsychotics Pramipexole Clinical Trial Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Weng JJ Wang LH Zhu H Xu WR Wei YM Wang ZY Yu WJ Li HF Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| description |
Jia Jun Weng,*,1 Li Hua Wang,*,1 Hao Zhu,2 Wen Rong Xu,1 Yu Mei Wei,1 Zhi Yang Wang,1 Wen Juan Yu,1 Hua Fang Li1,3–41Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University of Medicine, Shanghai, People’s Republic of China; 2Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University of Medicine, Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Psychotic Disorders, Shanghai, People’s Republic of China; 4Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China*These authors contributed equally to this workObjective: Some lines of evidence show that D2/D3 receptor partial agonist pramipexole may be effective in the treatment of extrapyramidal symptoms (EPS) and psychiatric symptoms of schizophrenia. Therefore, we analyzed whether a low dose of pramipexole (0.375–0.75 mg/day) has efficacy on EPS and symptoms of schizophrenia while maintaining tolerability.Methods: Ten subjects with EPS [including drug-induced parkinsonism (DIP) and akathisia] were recruited in a stage-1, open-label pilot study. All the subjects were treated with a low dose of pramipexole. The evaluations were performed at baseline, day 3, week 1, week 2, week 4, week 6, and week 8. The ratings of SAS, BARS, PANSS, CDSS, and CGI-S and adverse effects (AE) were recorded in every visit.Results: SAS total scores decreased significantly during the study in patients with DIP (P<0.001), and mild AEs were detected. Treatments with pramipexole did not show an anti-akathisia effect during the study, while 2 subjects experienced deterioration of akathisia and mood symptoms. The psychiatric symptoms of schizophrenia showed a trend of improvement during the study, but there was no improvement in depressive mood.Conclusion: A low dose of pramipexole can significantly relieve antipsychotic-induced parkinsonism, but not akathisia. Improvements in psychiatric symptoms of schizophrenia were found, but the results of this study need to be validated in a larger sample. No improvement of mood disorder was detected.Keywords: extrapyramidal symptoms, antipsychotics, pramipexole, clinical trial |
| format |
article |
| author |
Weng JJ Wang LH Zhu H Xu WR Wei YM Wang ZY Yu WJ Li HF |
| author_facet |
Weng JJ Wang LH Zhu H Xu WR Wei YM Wang ZY Yu WJ Li HF |
| author_sort |
Weng JJ |
| title |
Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| title_short |
Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| title_full |
Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| title_fullStr |
Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| title_full_unstemmed |
Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| title_sort |
efficacy of low-dose d2/d3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/ae1f261d9a0849728efebc5889ba9b88 |
| work_keys_str_mv |
AT wengjj efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT wanglh efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT zhuh efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT xuwr efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT weiym efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT wangzy efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT yuwj efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy AT lihf efficacyoflowdosed2d3nbsppartialnbspagonistpramipexoleonneurolepticinducedextrapyramidalsymptomsandsymptomsofschizophreniaastage1openlabelpilotstudy |
| _version_ |
1718398431467143168 |